Parkinson’s Disease

Safinamide Approved as Adjunctive Therapy for Parkinson's

Safinamide Approved as Adjunctive Therapy for Parkinson's

By

The US FDA has approved safinamide as adjunctive therapy in Parkinson's disease to increase "on" time

Timed Light Therapy May Benefit Sleep in Parkinson's

Timed Light Therapy May Benefit Sleep in Parkinson's

By

Improvements in excessive daytime sleepiness and daytime alertness were observed in the bright light therapy group.

Parkinsonian Disorder Differentiation Using Blood Biomarker

Parkinsonian Disorder Differentiation Using Blood Biomarker

By

Neurofilament light chain, a blood biomarker, demonstrated high accuracy for distinguishing atypical parkinsonian disorders from Parkinson's disease.

VIDEO: Dysfunctional Mitochondrial DNA May Play a Role in Parkinson's Disease

VIDEO: Dysfunctional Mitochondrial DNA May Play a Role in Parkinson's Disease

New findings suggest that dysregulation of mitochondrial DNA homeostasis may be a key factor in the pathogenesis of neuronal loss in people with Parkinson's disease.

Cognitive Stress Impacts Levodopa Efficacy in Parkinson's

Cognitive Stress Impacts Levodopa Efficacy in Parkinson's

During cognitive co-activation, the levodopa effect was significantly smaller.

FDA Reviewing Potential Treatment for Levodopa-Induced Dyskinesia

FDA Reviewing Potential Treatment for Levodopa-Induced Dyskinesia

By

The FDA has accepted the NDA for ADS-5102 for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease.

Developing a Model for Predicting Cognitive Impairment in Parkinson's

Developing a Model for Predicting Cognitive Impairment in Parkinson's

By

A combination of age and clinical scores better predicted cognitive impairment than age alone.

Adjunctive Safinamide Increases On Time in Parkinson's Disease

Adjunctive Safinamide Increases On Time in Parkinson's Disease

By

Adjunctive treatment with safinamide helps increase "on" time in patients with Parkinson's disease.

Gene Mutation, Age Linked to Early-Onset Parkinson's Disease

Gene Mutation, Age Linked to Early-Onset Parkinson's Disease

Mutated GCH1 gene was associated with a 23% increased risk of Parkinson's disease, especially in men 50 years or younger.

More Evidence Favoring Inhaled Levodopa for Parkinson's

More Evidence Favoring Inhaled Levodopa for Parkinson's

A powdered version of the common treatment may help to relieve "off" periods.

Whole Body Vibration, Exercise May Improve Motor Performance In Parkinson's

Whole Body Vibration, Exercise May Improve Motor Performance In Parkinson's

By

Pharmacologic intervention is the current standard of care for Parkinson's disease, yet medications frequently fail to control some symptoms, including tremor and postural instability.

Sign Up for Free e-newsletters